$1 Billion Market Cap @ Algernon Pharmaceuticals...
shell3
166,945,269 Issued and outstanding after new Private Placement
...equals $6 per share.
Bellus Health damn near did it ($1B) with a failed Phase 2 clinical trial for Chronic Cough.
Of note to folk:
Algernon Pharmaceuticals’ NP-120 (Ifenprodil) Outperforms Merck’s Phase 3 Drug MK-7264 (Gefapixant) in an Acute Cough Study by 110%
Unlike Gefapixant, Ifenprodil has no known taste disturbance, which is similar to Bellus Health’s Phase 2 asset BLU-5937. Note: Bellus Health Inc. has reported that BLU-5937 had comparable efficacy to Merck’s MK-7264 (Gefapixant) in a guinea pig cough inhibition study that they conducted
Algernon's NP-120 outperforms both of them.
The Key is get to a Data Readout while we're still young.
AI
